CLEC12A and acute myeloid leukemia: Preclinical studies have reported that the generation of CAR-NK cells targeting CLL-1 using CAR constructs with CLL-1-specific scFv of various sizes and flexibility allowed the generation of CLL1 CAR-NK cells exhibiting cytotoxicity against primary AML blasts, but devoid of toxicity against allogeneic normal HSPCs [62].